On the architecture of translational research designed to control chronic lymphocytic leukemia

由 Hallek, Michael
發表在 Hematology Am Soc Hematol Educ Program (2018)

Management of chronic lymphocytic leukemia

由 Ghia, Paolo, Hallek, Michael
出版 2014

Prognostication of chronic lymphocytic leukemia in the era of new agents

由 Eichhorst, Barbara, Hallek, Michael
發表在 Hematology Am Soc Hematol Educ Program (2016)

Optimizing frontline therapy of CLL based on clinical and biological factors

由 Fischer, Kirsten, Hallek, Michael
發表在 Hematology Am Soc Hematol Educ Program (2017)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

由 Krause, Günter, Hassenrück, Floyd, Hallek, Michael
發表在 Drug Des Devel Ther (2018)

Sequential and combination treatments with novel agents in chronic lymphocytic leukemia

由 Fürstenau, Moritz, Hallek, Michael, Eichhorst, Barbara
發表在 Haematologica (2019)

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

由 Eichhorst, Barbara, Fürstenau, Moritz, Hallek, Michael
發表在 Hematology Am Soc Hematol Educ Program (2019)

Cell line‐based assessment of BTK inhibitors

由 Krause, Günter, Hassenrück, Floyd, Hallek, Michael
發表在 Br J Pharmacol (2020)

Relevant Cytokines in the B Cell Lymphoma Micro-Environment

由 Krause, Günter, Hassenrück, Floyd, Hallek, Michael
發表在 Cancers (Basel) (2020)

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

由 Fischer, Kirsten, Al-Sawaf, Othman, Hallek, Michael
發表在 Hematology Am Soc Hematol Educ Program (2020)

Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice

由 Kohlhas, Viktoria, Hallek, Michael, Nguyen, Phuong-Hien
發表在 Blood Adv (2020)

Multiple Myeloma: Increasing Evidence for a Multistep Transformation Process

由 Hallek, Michael, Bergsagel, P. Leif, Anderson, Kenneth C.
出版 1998

The Treatment of Chronic Lymphatic Leukemia

由 von Tresckow, Julia, Eichhorst, Barbara, Bahlo, Jasmin, Hallek, Michael
發表在 Dtsch Arztebl Int (2019)

Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?

由 Fürstenau, Moritz, De Silva, Nisha, Eichhorst, Barbara, Hallek, Michael
發表在 Hemasphere (2019)

Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma

由 Hansen, Hinrich P., Paes Leme, Adriana F., Hallek, Michael
發表在 Front Immunol (2020)

Does Exercise Have a Preventive Effect on Secondary Lymphedema in Breast Cancer Patients Following Local Treatment? - A Systematic Review

由 Baumann, Freerk T., Reike, Alexandra, Hallek, Michael, Wiskemann, Joachim, Reimer, Vanessa
發表在 Breast Care (Basel) (2018)

Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors

由 Ried, Martin U., Girod, Anne, Leike, Kristin, Büning, Hildegard, Hallek, Michael
出版 2002

Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia

由 Koehler, Philipp, Schmidt, Patrick, Hombach, Andreas A., Hallek, Michael, Abken, Hinrich
出版 2012

Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review

由 Al-Sawaf, Othman, Cramer, Paula, Goede, Valentin, Hallek, Michael, Pflug, Natali
發表在 Ther Adv Hematol (2017)

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia

由 Elter, Thomas, Kilp, Julia, Borchmann, Peter, Schulz, Holger, Hallek, Michael, Engert, Andreas
出版 2009